AdAlta Ltd (1AD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
49
About the Report
About the Report
Summary
AdAlta Ltd (AdAlta), formerly AdAlta Pty Ltd, is a biotechnology company that discovers and develops new class of protein therapeutics for wide range of human diseases. The company's lead i-body candidate, AD-114, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its i-body products are developed using proprietary technology platform that delivers specific biologics and affinity against a variety of therapeutic and diagnostic targets such as cell surface, membrane spanning and complex proteins. AdAlta utilizes the i-body technology to create a pipeline of new drugs for treating fibrotic diseases. The company collaborates with various pharmaceutical and biotech companies in Australia. AdAlta is headquartered in Melbourne, Victoria, Australia.
AdAlta Ltd (1AD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
AdAlta Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AdAlta Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AdAlta Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
AdAlta Expands Collaboration with The Alfred Hospital 11
AdAlta Enters into Agreement with XL-protein 12
Crossbeta Biosciences Enters Into Agreement With AdAlta For Drug Discovery 13
Licensing Agreements 14
Crossbeta Biosciences Enters into Licensing Agreement with AdAlta 14
Equity Offering 15
AdAlta to Raise Funds through Share Purchase Plan 15
AdAlta Raises USD3.1 Million in Private Placement of Shares 16
AdAlta Raises USD7.5 Million in IPO 17
AdAlta Ltd-Key Competitors 18
AdAlta Ltd-Key Employees 19
AdAlta Ltd-Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Feb 20, 2018: AdAlta: Half year report for the half-year ended 31 December 2017 21
Apr 26, 2017: AdAlta Announces Quarterly Cash Flow Statement 23
Jan 31, 2017: AdAlta: Quarterly Cash Flow Statement 25
Government and Public Interest 27
Jul 25, 2018: AdAlta's i-body platform: reaching for the high-hanging fruit 27
Jul 24, 2017: AdAlta and La Trobe awarded SIEF Business Fellowship grant to identify novel i-bodies 28
Product News 29
12/07/2017: NHMRC USD 768,000 Grant for Development of AD-114 in Chronic Kidney Disease 29
11/13/2017: AdAlta to present at Anti-Fibrotic Drug Development Summit in Boston 30
08/21/2017: Compelling new lung disease treatment pioneered in Victoria gains global attention alongside top researchers and drug developers 31
05/08/2017: AdAlta to present eye fibrosis data at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 32
05/01/2017: AdAlta releases Idiopathic Pulmonary Fibrosis Overview Document 33
01/16/2018: Researcher looks to next generation antibody treatment for Chronic Kidney Disease 34
01/08/2018: AdAlta to present at the Biotech Showcase in San Francisco 35
Product Approvals 36
Jan 18, 2017: AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic pulmonary disease 36
Clinical Trials 37
Apr 18, 2018: AdAlta to advance improved lung fibrosis therapy, AD-214 37
Nov 22, 2017: AdAlta gets commercial-ready after pre-clinical safety studies show promising results 38
Sep 19, 2017: AdAlta announces additional, positive safety data of AD-114 in non-human primates 39
Sep 04, 2017: AdAlta to present kidney fibrosis data at Australian and New Zealand Society of Nephrology Annual Scientific Meeting 40
Jul 18, 2017: AD-114 safe in non-human primates and manufacturing progress update 41
Jan 09, 2017: AdAlta Announces Positive Pre-clinical Data Showing Lead Drug Candidate Has Broad Fibrosis Treatment Potential 43
Other Significant Developments 44
Oct 17, 2018: AdAlta: Quarterly cash flow statement 44
Jul 16, 2018: AdAlta: Quarterly Cash Flow Statement Quarter ended 30 June 2018 46
Jul 27, 2017: AdAlta: Announces Quarterly Cash Flow Statement 47
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
List of Figure
List of Figures
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
AdAlta Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AdAlta Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AdAlta Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
AdAlta Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AdAlta Expands Collaboration with The Alfred Hospital 11
AdAlta Enters into Agreement with XL-protein 12
Crossbeta Biosciences Enters Into Agreement With AdAlta For Drug Discovery 13
Crossbeta Biosciences Enters into Licensing Agreement with AdAlta 14
AdAlta to Raise Funds through Share Purchase Plan 15
AdAlta Raises USD3.1 Million in Private Placement of Shares 16
AdAlta Raises USD7.5 Million in IPO 17
AdAlta Ltd, Key Competitors 18
AdAlta Ltd, Key Employees 19
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.